HAI T TRAN

TitleAssociate Professor
InstitutionMD Anderson
DepartmentThoracic Head & Neck Medical Oncology
Address1400 Holcombe Blvd
Houston TX 77030-4008
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Massarelli E, Lin H, Ginsberg LE, Tran HT, Lee JJ, Canales JR, Williams MD, Blumenschein GR, Lu C, Heymach JV, Kies MS, Papadimitrakopoulou V. Phase II trial of everolimus and erlotinib in patients with platinum-resistant recurrent and/or metastatic head and neck squamous cell carcinoma. Ann Oncol. 2015 Jul; 26(7):1476-80. PMID: 26025965; PMCID: PMC4855241.
      Citations: 34     Fields:    Translation:HumansCTClinical Trials
    2. Lieu CH, Tran H, Jiang ZQ, Mao M, Overman MJ, Lin E, Eng C, Morris J, Ellis L, Heymach JV, Kopetz S. The association of alternate VEGF ligands with resistance to anti-VEGF therapy in metastatic colorectal cancer. PLoS One. 2013; 8(10):e77117. PMID: 24143206; PMCID: PMC3797099.
      Citations: 55     Fields:    Translation:HumansCTClinical Trials
    3. Tsao AS, Liu S, Lee JJ, Alden CM, Blumenschein GR, Herbst R, Davis SE, Kim E, Lippman S, Heymach J, Tran H, Tang X, Wistuba I, Hong WK. Clinical and biomarker outcomes of the phase II vandetanib study from the BATTLE trial. J Thorac Oncol. 2013 May; 8(5):658-61. PMID: 23584298; PMCID: PMC5118909.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    4. O'Donnell P, Ferguson J, Shyu J, Current R, Rehage T, Tsai J, Christensen M, Tran HB, Chien SS, Shieh F, Wei W, Lawrence HJ, Wu L, Schilling R, Bloom K, Maltzman W, Anderson S, Soviero S. Analytic performance studies and clinical reproducibility of a real-time PCR assay for the detection of epidermal growth factor receptor gene mutations in formalin-fixed paraffin-embedded tissue specimens of non-small cell lung cancer. BMC Cancer. 2013 Apr 27; 13:210. PMID: 23621958; PMCID: PMC3660201.
      Citations: 17     Fields:    Translation:Humans
    5. Zurita AJ, Jonasch E, Wang X, Khajavi M, Yan S, Du DZ, Xu L, Herynk MH, McKee KS, Tran HT, Logothetis CJ, Tannir NM, Heymach JV. A cytokine and angiogenic factor (CAF) analysis in plasma for selection of sorafenib therapy in patients with metastatic renal cell carcinoma. Ann Oncol. 2012 Jan; 23(1):46-52. PMID: 21464158; PMCID: PMC3276320.
      Citations: 50     Fields:    Translation:HumansCTClinical Trials
    6. Tran HT, Zinner RG, Blumenschein GR, Oh YW, Papadimitrakopoulou VA, Kim ES, Lu C, Malik M, Lum BL, Herbst RS. Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial (TRIBUTE) of paclitaxel and carboplatin combined with erlotinib or placebo in patients with advanced Non-small Cell Lung Cancer (NSCLC). Invest New Drugs. 2011 Jun; 29(3):499-505. PMID: 20094773.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    7. Salmon S, Chen H, Chen S, Herbst R, Tsao A, Tran H, Sandler A, Billheimer D, Shyr Y, Lee JW, Massion P, Brahmer J, Schiller J, Carbone D, Dang TP. Classification by mass spectrometry can accurately and reliably predict outcome in patients with non-small cell lung cancer treated with erlotinib-containing regimen. J Thorac Oncol. 2009 Jun; 4(6):689-96. PMID: 19404214; PMCID: PMC3563261.
      Citations: 12     Fields:    Translation:HumansCTClinical Trials
    8. Zhong L, Roybal J, Chaerkady R, Zhang W, Choi K, Alvarez CA, Tran H, Creighton CJ, Yan S, Strieter RM, Pandey A, Kurie JM. Identification of secreted proteins that mediate cell-cell interactions in an in vitro model of the lung cancer microenvironment. Cancer Res. 2008 Sep 01; 68(17):7237-45. PMID: 18757440; PMCID: PMC2562343.
      Citations: 36     Fields:    Translation:AnimalsCells
    9. Becerra CR, Verma UN, Tran HT, Tavana D, Williams NS, Frenkel EP. Phase I dose escalation study with irinotecan, capecitabine, epirubicin, and granulocyte colony-stimulating factor support for patients with solid malignancies. Am J Clin Oncol. 2008 Jun; 31(3):219-25. PMID: 18525298.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    10. Johnson FM, Saigal B, Tran H, Donato NJ. Abrogation of signal transducer and activator of transcription 3 reactivation after Src kinase inhibition results in synergistic antitumor effects. Clin Cancer Res. 2007 Jul 15; 13(14):4233-44. PMID: 17634553.
      Citations: 36     Fields:    Translation:HumansCells
    11. Lippman SM, Lee JJ, Martin JW, El-Naggar AK, Xu X, Shin DM, Thomas M, Mao L, Fritsche HA, Zhou X, Papadimitrakopoulou V, Khuri FR, Tran H, Clayman GL, Hittelman WN, Hong WK, Lotan R. Fenretinide activity in retinoid-resistant oral leukoplakia. Clin Cancer Res. 2006 May 15; 12(10):3109-14. PMID: 16707609.
      Citations: 22     Fields:    Translation:HumansCTClinical Trials
    12. Shaughnessy P, Alexander W, Tran H, Ririe D, Splichal J, Pollack M, Bachier C, LeMaistre C. Phase I and pharmacokinetic study of once-daily dosing of intravenously administered busulfan in the setting of a reduced-intensity preparative regimen and allogeneic hematopoietic stem cell transplantation as immunotherapy for renal cell carcinoma. Mil Med. 2006 Feb; 171(2):161-5. PMID: 16578989.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    13. Lee HY, Oh SH, Woo JK, Kim WY, Van Pelt CS, Price RE, Cody D, Tran H, Pezzuto JM, Moriarty RM, Hong WK. Chemopreventive effects of deguelin, a novel Akt inhibitor, on tobacco-induced lung tumorigenesis. J Natl Cancer Inst. 2005 Nov 16; 97(22):1695-9. PMID: 16288123.
      Citations: 55     Fields:    Translation:AnimalsCellsPHPublic Health
    14. Herbst RS, Johnson DH, Mininberg E, Carbone DP, Henderson T, Kim ES, Blumenschein G, Lee JJ, Liu DD, Truong MT, Hong WK, Tran H, Tsao A, Xie D, Ramies DA, Mass R, Seshagiri S, Eberhard DA, Kelley SK, Sandler A. Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. J Clin Oncol. 2005 Apr 10; 23(11):2544-55. PMID: 15753462.
      Citations: 130     Fields:    Translation:HumansCTClinical Trials
    15. Tran H, Petropoulos D, Worth L, Mullen CA, Madden T, Andersson B, Choroszy M, Nguyen J, Webb SK, Chan KW. Pharmacokinetics and individualized dose adjustment of intravenous busulfan in children with advanced hematologic malignancies undergoing allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2004 Nov; 10(11):805-12. PMID: 15505611.
      Citations: 11     Fields:    Translation:Humans
    16. Tran HT, Blumenschein GR, Lu C, Meyers CA, Papadimitrakopoulou V, Fossella FV, Zinner R, Madden T, Smythe LG, Puduvalli VK, Munden R, Truong M, Herbst RS. Clinical and pharmacokinetic study of TNP-470, an angiogenesis inhibitor, in combination with paclitaxel and carboplatin in patients with solid tumors. Cancer Chemother Pharmacol. 2004 Oct; 54(4):308-14. PMID: 15184994.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    17. Gordon N, Mullen CA, Tran H, Worth L, Gomez Almaguer D, Chan KW. Fludarabine and once-daily intravenous busulfan for allogeneic bone marrow transplantation for Chediak-Higashi syndrome. J Pediatr Hematol Oncol. 2003 Oct; 25(10):824-6. PMID: 14528111.
      Citations: 3     Fields:    Translation:Humans
    18. Chan KW, Mullen CA, Worth LL, Choroszy M, Koontz S, Tran H, Slopis J. Lorazepam for seizure prophylaxis during high-dose busulfan administration. Bone Marrow Transplant. 2002 Jun; 29(12):963-5. PMID: 12098063.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    19. Russell JA, Tran HT, Quinlan D, Chaudhry A, Duggan P, Brown C, Stewart D, Ruether JD, Morris D, Glick S, Gyonyor E, Andersson BS. Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. Biol Blood Marrow Transplant. 2002; 8(9):468-76. PMID: 12374451.
      Citations: 84     Fields:    Translation:HumansCTClinical Trials
    20. Herbst RS, Lee AT, Tran HT, Abbruzzese JL. Clinical studies of angiogenesis inhibitors: the University of Texas MD Anderson Center Trial of Human Endostatin. Curr Oncol Rep. 2001 Mar; 3(2):131-40. PMID: 11177745.
      Citations: 11     Fields:    Translation:Humans
    21. Tran HT, Madden T, Petropoulos D, Worth LL, Felix EA, Sprigg-Saenz HA, Choroszy M, Danielson M, Przepiorka D, Chan KW. Individualizing high-dose oral busulfan: prospective dose adjustment in a pediatric population undergoing allogeneic stem cell transplantation for advanced hematologic malignancies. Bone Marrow Transplant. 2000 Sep; 26(5):463-70. PMID: 11019834.
      Citations: 13     Fields:    Translation:Humans
    22. Madden T, Tran HT, Beck D, Huie R, Newman RA, Pusztai L, Wright JJ, Abbruzzese JL. Novel marine-derived anticancer agents: a phase I clinical, pharmacological, and pharmacodynamic study of dolastatin 10 (NSC 376128) in patients with advanced solid tumors. Clin Cancer Res. 2000 Apr; 6(4):1293-301. PMID: 10778954.
      Citations: 20     Fields:    Translation:HumansAnimalsCTClinical Trials
    23. Andersson BS, Madden T, Tran HT, Hu WW, Blume KG, Chow DS, Champlin RE, Vaughan WP. Acute safety and pharmacokinetics of intravenous busulfan when used with oral busulfan and cyclophosphamide as pretransplantation conditioning therapy: a phase I study. Biol Blood Marrow Transplant. 2000; 6(5A):548-54. PMID: 11071260.
      Citations: 27     Fields:    Translation:HumansCTClinical Trials
    24. Worth L, Tran H, Petropoulos D, Culbert S, Mullen C, Roberts W, Przepiorka D, Chan K. Hematopoietic stem cell transplantation for childhood myeloid malignancies after high-dose thiotepa, busulfan and cyclophosphamide. Bone Marrow Transplant. 1999 Nov; 24(9):947-52. PMID: 10556952.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    25. Vey N, Kantarjian H, Tran H, Beran M, O'Brien S, Bivins C, Giles F, Cortes J, Cheson B, Arbuck S, Estey E. Phase I and pharmacologic study of 9-aminocamptothecin colloidal dispersion formulation in patients with refractory or relapsed acute leukemia. Ann Oncol. 1999 May; 10(5):577-83. PMID: 10416008.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    26. Abramson DH, Frank CM, Chantada GL, de Totah AB, de Pifano IT, Gomez RT, Fandino AT, Tran HT, Madden TJ, Dunkel IJ, Ram?rez GT. Intraocular carboplatin concentrations following intravenous administration for human intraocular retinoblastoma. Ophthalmic Genet. 1999 Mar; 20(1):31-6. PMID: 10415463.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    27. Mendelsohn ME, Abramson DH, Madden T, Tong W, Tran HT, Dunkel IJ. Intraocular concentrations of chemotherapeutic agents after systemic or local administration. Arch Ophthalmol. 1998 Sep; 116(9):1209-12. PMID: 9747681.
      Citations: 16     Fields:    Translation:AnimalsCells
    28. Kornblau SM, Estey E, Madden T, Tran HT, Zhao S, Consoli U, Snell V, Sanchez-Williams G, Kantarjian H, Keating M, Newman RA, Andreeff M. Phase I study of mitoxantrone plus etoposide with multidrug blockade by SDZ PSC-833 in relapsed or refractory acute myelogenous leukemia. J Clin Oncol. 1997 May; 15(5):1796-802. PMID: 9164187.
      Citations: 14     Fields:    Translation:HumansCTClinical Trials
    29. Erratum. Cancer. 118:2560.
    30. Germline Mutation of T790M and Dual/Multiple EGFR Mutations in Patients With Lung Adenocarcinoma. Clinical Lung Cancer.
    31. Detection of T790M, the acquired resistance EGFR mutation, by tumor biopsy versus noninvasive blood-based analyses. Clinical Cancer Research. 22:1103-1110.
    32. KDR amplification is associated with VEGF-induced activation of the mTOR and invasion pathways but does not predict clinical benefit to the VEGFR TKI vandetanib. Clinical Cancer Research. 22:1940-1950.
    33. A randomized phase II trial of short-course androgen deprivation therapy with or without bevacizumab for patients with recurrent prostate cancer after definitive local therapy. Journal of Clinical Oncology. 34:1913-1920.
    34. Phase I study of vandetanib with radiation therapy with or without cisplatin in locally advanced head and neck squamous cell carcinoma. Head and Neck.
    35. Antiangiogenic treatment with endostatin results in uncoupling of blood flow and glucose metabolism in human tumors. Clinical Positron Imaging (Netherlands). 3:151.
    36. A practical synthesis and X-ray crystallographic analysis of dithymoquinone, a photodimer of thymoquinone. Letters in Organic Chemistry. 9:762-766.
    37. Hepatotoxicity with Vismodegib. Drugs in R and D. 1-8.
    38. First pass FDG measured blood flow in tumors. Clinical Positron Imaging (Netherlands). 3:153.
    39. Effective drug delivery, in vitro and in vivo, by carbon-based nanovectors noncovalently loaded with unmodified paclitaxel (ACS Nano (2010) 4 (4621-4636)). ACS Nano. 4:5512.
    TRAN's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (233)
    Explore
    _
    Co-Authors (38)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _